Stock Market Wire News Logo
Stock Market Wire News Logo
    • Login
    • Sign Up

Ad

Investor Relations

ABUS Stock - Arbutus Biopharma Corporation Stock Trading


home / stock / abus

ABUS ABUS Quote ABUS Short ABUS News ABUS Articles ABUS Message Board

MWN AI Summary *

Arbutus Biopharma Corporation (NASDAQ: ABUS) is a biopharmaceutical company focused on developing innovative therapeutics for the treatment of hepatitis B virus (HBV) infections and other viral diseases. Founded in 2008 and based in Vancouver, Canada, the company aims to address the significant unmet medical needs associated with chronic HBV, which affects millions of people worldwide and can lead to severe liver disease and increased mortality risk.

Arbutus has built a diverse pipeline of drug candidates, leveraging its proprietary lipid-based delivery technologies and novel antiviral therapies to combat HBV. The company's lead product candidate, AB-729, is an RNAi therapeutic designed to silence HBV genes, thus reducing viral loads in infected patients. AB-729 is currently undergoing clinical trials to assess its safety and efficacy, and early clinical data has shown promise in reducing hepatitis B surface antigens, a key marker of viral infection.

Additionally, Arbutus is advancing AB-836, a capsid inhibitor that aims to disrupt the HBV life cycle by targeting the viral core protein. This combination of therapies reflects Arbutus’s strategy of layering multiple mechanisms to achieve functional cure and improved patient outcomes.

The recent financial performance of Arbutus showcases careful management of resources, ensuring sufficient capital to advance its clinical programs. The company has been proactive in collaborating with partners and institutions, seeking to leverage external expertise and investments to bolster its development efforts.

Investors are closely monitoring Arbutus as it navigates the complexities of clinical trials and regulatory processes in the biopharmaceutical landscape. The advancements in its pipeline, alongside the pressing global need for effective HBV treatments, position Arbutus Biopharma as a player to watch in the biotechnology sector.

MWN AI Analysis *

As of October 2023, Arbutus Biopharma Corporation (NASDAQ: ABUS) presents an intriguing opportunity for investors, particularly those focused on the biotech sector. The company is primarily engaged in the development of therapies for chronic hepatitis B infection, which remains a significant global health issue affecting millions of patients and presenting an ongoing demand for effective treatments.

Arbutus has made notable advancements with its pipeline, particularly its lead asset, AB-729, an RNA-targeted therapy that has shown promising results in early-stage clinical trials. The drug's mechanism of action aims to address the virus by targeting its RNA, potentially leading to functional cures. The results from the ongoing trials, expected to be released in the coming months, are pivotal and could create volatility in the stock price, depending on the outcomes.

Moreover, the company’s strategic partnerships, including collaborations with larger pharmaceutical entities, bolster its research capabilities and financial stability. These alliances not only enhance Arbutus's credibility in the market but also provide essential funding, reducing risk for potential investors.

However, prospects in the biotech sector come with inherent risks. The FDA approval process can be lengthy and unpredictable. Additionally, the biotech industry is characterized by high research costs and the possibility of setbacks in clinical trials. Investors should remain vigilant of external market factors, including healthcare regulations and pricing pressures that could impact the profitability of new therapies.

In conclusion, while Arbutus Biopharma shows promise with its innovative treatments and solid pipeline, investors should proceed with caution. A balanced approach that takes into consideration the potential for both risk and reward is advisable. Keeping an eye on trial results, regulatory news, and market trends will be crucial for making informed investment decisions regarding ABUS.

* MWN AI Summary and Analysis is based on asking OpenAI to summarize and analyze the company and stock symbol.


About | Arbutus Biopharma Corporation (NASDAQ:ABUS)

Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. It is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.

Quote | Arbutus Biopharma Corporation (NASDAQ:ABUS)

Last:$3.08
Change Percent: 0.64%
Open:$3.1
Close:$3.08
High:$3.15
Low:$3.05
Volume:1,052,561
Last Trade Date Time:05/16/2025 03:39:42 pm

News | Arbutus Biopharma Corporation (NASDAQ:ABUS)

  • Arbutus Biopharma GAAP EPS of -$0.13 misses by $0.03, revenue of $1.76M beats by $0.17M

    2025-05-14 07:50:25 ET More on Arbutus Biopharma Arbutus Biopharma: A Wing And A Prayer Arbutus announces a 57% workforce reduction Arbutus appoints Lindsay Androski as CEO Seeking Alpha’s Quant Rating on Arbutus Biopharma Historical earnings d...

    • May 14, 2025 07:50:25 am

    • |
    • SeekingAlpha
    • |
      • ABUS Stock
      • ABUS Quote
      • ABUS Short
      • ABUS News
      • ABUS Articles
      • ABUS Message Board
  • Expected US Company Earnings on Thursday, May 8th, 2025

    Ironwood Pharmaceuticals Inc. (IRWD) is expected to report $-0.05 for Q1 2025 CaliberCos Inc. (CWD) is expected to report $-0.4 for Q1 2025 BlackRock TCP Capital Corp. (TCPC) is expected to report $0.34 for Q1 2025 INmune Bio Inc. (INMB) is expected to report $-0.43 for Q1 2025 No...

    • May 08, 2025 07:00:54 am

    • |
    • US Earnings Reports
    • |
      • ABUS Stock
      • ABUS Quote
      • ABUS Short
      • ABUS News
      • ABUS Articles
      • ABUS Message Board

Message Board Posts | Arbutus Biopharma Corporation (NASDAQ:ABUS)

Subject By Source When
$ABUS Arbutus Biopharma Corporation mick investorshub 04/30/2023 11:03:50 PM
Arbutus Biopharma Corporation (Nasdaq: $ABUS), a clinical-stage biopharmaceutical mick investorshub 04/18/2023 8:07:45 PM
With a median price-to-sales (or "P/S") ratio of mick investorshub 04/18/2023 8:06:48 PM
$ABUS Arbutus Biopharma Corporation mick investorshub 04/15/2023 6:42:52 PM
rare form / https://investorshub.advfn.com/Arbutus-Biopharma-Corporation-17838#: mick investorshub 04/15/2023 6:42:33 PM
Stock Information

Get ABUS Alerts

News, Short Squeeze, Breakout and More Instantly...

Arbutus Biopharma Corporation Company Name:

ABUS Stock Symbol:

NASDAQ Market:

0.64% G/L:

$3.08 Last:

1,052,561 Volume:

$3.10 Open:

$3.08 Close:

Arbutus Biopharma Corporation Website:

Arbutus Biopharma Corporation Logo

Ad

Investor Relations
RECENT ABUS NEWS
  • ABUS - Expected US Company Earnings on Thursday, May 8th, 2025

    Ironwood Pharmaceuticals Inc. (IRWD) is expected to report $-0.05 for Q1 2025 CaliberCos Inc. (CWD) is expected to report $-0.4 for Q1 2025 BlackRock TCP Capital Corp. (TCPC) is expected to report $0.34 for Q1 2025 INmune Bio Inc. (INMB) is expected to report $-0.43 for Q1 2025 No...

  • ABUS - Expected US Company Earnings on Thursday, March 27th, 2025

    HG Holdings Inc (STLY) is expected to report for quarter end 2024-12-31 Savara Inc. (SVRA) is expected to report $-0.11 for Q4 2024 Reborn Coffee Inc. (REBN) is expected to report for quarter end 2024-12-31 VSee Health Inc. (VSEE) is expected to report for Q4 2024 IceCure Medical ...

  • ABUS - Expected US Company Earnings on Thursday, March 20th, 2025

    Papaya Growth Opportunity Corp. I (PPYA) is expected to report for quarter end 2024-12-31 KinderCare Learning Companies Inc. (KLC) is expected to report $0.04 for Q4 2024 Recordati SpA (RCDTF) is expected to report for quarter end 2024-12-31 InflaRx N.V. (IFRX) is expected to report $...

  • Research
  • Stock Search
  • News Releases
  • Articles
  • Topics
  • Message Boards
  • Trending Stocks
  • Trending Feed
  • Trending Alerts
  • Watchlist
  • Short Information
  • Stock Wall
  • Link Twitter
  • Sign Up
  • Login
  • Contact

Link your X Account

Link your X Account to Market Wire News

When you linking your X Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your X account.

Be alerted of any news about your stocks and see what other stocks are trending.



Trending Stock Alerts

Trending Stock Alerts

Our Next Stock Alert could be Coming in Minutes!

Sign Up Today To Get Full Access To Our Next Stock Report!

  • Day Before Email and Text Notifications of New Alerts
  • Day of Email and Text Notifications
  • Trending Stocks, Watchlist and News Releases
  • Mobile App Notifications

Trending Stock Alerts

Get ABUS Alerts

Get ABUS Alerts

News, Short Squeeze, Breakout and More Instantly...

Sign up or login to continue

Sign up or login to continue.


Forgot password?




Mobile Number Subscribers

Market Wire News provides notifications to customers about updates, service, reminders, or products. Current and new customers of Market Wire News will enter their mobile numbers on a web opt-in form https://marketwirenews.com. Supported Carriers are as follows Alltel, AT&T, Cincinnati Bell, Dobson Cellular Systems, Inter Op, MetroPCS®, Nextel Communications, Sprint PCS, T-Mobile®, U.S. Cellular®, Verizon Wireless, and Virgin Mobile U.S. T-Mobile® is not liable for delayed or undelivered messages. There are no premium charges for joining Market Wire News service. Message and data rates may apply. Subscribers to Market Wire News service may receive up to 500 per month.

How to Opt Out

To opt-out of the Market Wire News program, send or text STOP, END, QUIT, CANCEL or UNSUBSCRIBE to (844) 931-3999. An unsubscribe message will be sent to your number confirming the cancellation, but no more messages will be sent after that one.

Mobile Support

For support or information about a Market Wire News, send or text HELP to (844) 931-3999. Optionally, you may email support@marketwirenews.com.


Disclaimer

This electronic content is for the purposes of solicitation subscriptions for Market Wire News. Market Wire News expects to generate new advertisement revenue resulting from the distribution of this electronic content. The amount of which is unknown at this time. Market Wire News is not a registered investment adviser or broker-dealer. This electronic content does not provide a professional analysis of a any stock financial position. any stock's financial position and all other information regarding the featured Company should be verified directly with any stock. This electronic content is provided as an information service only, and any statements and opinions in this electronic content should not be construed as an offer or solicitation to buy or sell any security. Market Wire News accepts no liability for any loss arising from an investor's reliance on or use of this electronic content. An investment in any company is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. Market Wire News does not own, buy, sell or plans to own, buy, sell, and of any stock's shares. This electronic content contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Please read our full disclaimer for compensation and more detailed information.

Advertise

Brand your company, advertise your products or services with our ad programs.

Advertise

Research

Stock Search

News Releases

Articles

Message Boards

Trending Stocks

Short Information

Stock Wall

Members

Log In

Sign Up

Stay Connected

| X

| Facebook

| BlueSky

| LinkedIn

| Telegram

| Discord


Contact

Privacy

Terms of Service

Disclaimer

© 2025 Market Wire News 1